Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals

Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, combining their operations and resources to create a more diversified company focused on central nervous system biopharmaceuticals. The combined company plans to use its broader portfolio of marketed medicines and increased financial flexibility to strengthen its market position and support long-term growth. The article reports no financial terms or stock-price impact.